A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial

CONCLUSIONS: This is the first prospective trial of hormonal therapy in GCTs. Although there was a high CBR, the objective response rate to anastrozole was much lower than the pooled response rates of >70% to AIs reported in most retrospective series and case reports. PARAGON demonstrates the importance of prospective trials in rare cancers and the need to reconsider the role of AIs as single agents in GCTs.PMID:34412908 | DOI:10.1016/j.ygyno.2021.07.024

Source: Gynecologic Oncology - August 20, 2021 Category: Cancer & Oncology Authors: Susana N Banerjee Monica Tang Rachel L O'Connell Katrin Sjoquist Andrew R Clamp David Millan Steven Nottley Rosemary Lord Vinod Menon Mullassery Marcia Hall Charlie Gourley Tony Bonaventura Jeffrey C Goh Peter Sykes Peter T Grant Orla McNally Laura Alexan Source Type: research